Security
Anavex Life Sciences Corp. Common Stock · AVXL
AVXLNASDAQCommon stockCurrentCIK 1314052Updated Oct 21, 2026
Name history
Thrifty Printing Inc. · through Jan 25, 2007
AVXL price & chart
Loading TradingView…
NASDAQ:AVXL on TradingView ↗About the company
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at www.anavex.com.
In the news
AVXL Stockholders Have Rights - If You Lost Money Investing in Anavex Life Sciences Corp. Contact Robbins LLP for Information About Recovering Your Losses ↗
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL ↗
Seeking Alpha
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens ↗
Anavex: Downgrading To Sell On Blarcamesine MAA Withdrawal For AD, Pipeline Change ↗
Anavex Life Sciences gains IND clearance for blarcamesine in Fragile X syndrome ↗
SEC disclosures
ANAVEX LIFE SCIENCES CORP. files 8-K: Material Event ↗
Recent filings
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Changes in Control of Registrant · Submission of Matters to a Vote of Security Holders
Items 5.01, 5.07
DEFA14A filing
DEFA14A filing
Show 5 more recent filings
Other Events
Items 8.01
DEFA14A filing
DEFA14A filing
Other Events
Items 8.01, 9.01
DEFA14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 120,139,000Source | 102,432,000Source | 141,535,000Source | 128,766,000Source | 117,139,000Source | 144,516,000Source | 132,989,000Source | 124,043,000Source | 103,815,000Source | 135,567,000Source | 154,386,000Source | 152,704,603Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 118,326,000Source | 101,164,000Source | 138,756,000Source | 127,422,000Source | 115,771,000Source | 139,386,000Source | 131,749,000Source | 120,775,000Source | 102,577,000Source | 132,187,000Source | 151,024,000Source | 149,157,861Source |
| Prepaid Expense and Other Assets, CurrentUSD | 818,000Source | 448,000Source | 1,059,000Source | 412,000Source | 702,000Source | 1,345,000Source | 396,000Source | 711,000Source | 429,000Source | 931,000Source | 653,000Source | 354,162Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 7,692,000Source | 11,474,000Source | 11,754,000Source | 7,059,000Source | 17,381,000Source | 9,558,000Source | 6,371,000Source | 13,128,000Source | 8,946,000Source | 15,304,000Source | 12,534,000Source | 10,213,561Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 93,000Source | 85,000Source | 85,000Source | 93,000Source | 85,000Source | 84,000Source | 93,000Source | 85,000Source | 87,000Source | 85,000Source | 82,000Source | 77,944Source |
| Retained Earnings (Accumulated Deficit)USD | -385,643,000Source | -372,621,000Source | -324,451,000Source | -393,467,000Source | -359,378,000Source | -312,237,000Source | -388,129,000Source | -348,182,000Source | -382,448,000Source | -336,071,000Source | -293,069,000Source | -245,563,783Source |
| Stockholders' Equity Attributable to ParentUSD | 112,447,000Source | 90,958,000Source | 129,781,000Source | 121,707,000Source | 99,758,000Source | 134,958,000Source | 126,618,000Source | 110,915,000Source | 94,869,000Source | 120,263,000Source | 141,852,000Source | 142,491,042Source |
| Additional Paid in Capital, Common StockUSD | 497,997,000Source | 463,494,000Source | 454,236,000Source | 515,081,000Source | 459,051,000Source | 447,345,000Source | 514,654,000Source | 459,012,000Source | 477,230,000Source | 456,249,000Source | 434,839,000Source | 387,976,881Source |
| Liabilities and EquityUSD | 120,139,000Source | 102,432,000Source | 141,535,000Source | 128,766,000Source | 117,139,000Source | 144,516,000Source | 132,989,000Source | 124,043,000Source | 103,815,000Source | 135,567,000Source | 154,386,000Source | 152,704,603Source |
| Current liabilities: | ||||||||||||
| Accounts Payable, CurrentUSD | 3,656,000Source | 6,740,000Source | 3,503,000Source | 2,520,000Source | 6,997,000Source | 3,726,000Source | 2,639,000Source | 4,567,000Source | 4,249,000Source | 9,627,000Source | 4,322,000Source | 3,824,777Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 4,036,000Source | 3,929,000Source | 7,334,000Source | 3,734,000Source | 9,555,000Source | 4,915,000Source | 2,927,000Source | 7,732,000Source | 3,892,000Source | 4,835,000Source | 7,295,000Source | 5,944,953Source |
| Preferred Stock, Value, Issued | — | —Source | — | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | -17,084,000Source | 4,324,000Source | 314,000Source | 1,449,000Source | 1,107,000Source | 2,055,000Source | 11,549,000Source | 9,438,000Source | 16,370,000Source | 18,379,242Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,610,000Source | -5,060,000Source | -5,378,000Source | 5,305,000Source | 497,000Source | -915,004Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 7,000Source | 358,492Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,151,000Source | -12,120,000Source | -39,044,000Source | -30,812,000Source | -27,785,000Source | -24,237,864Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 36,323,000Source | 708,000Source | 9,434,000Source | 11,975,000Source | 29,651,000Source | 21,287,980Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 118,326,000Source | 101,164,000Source | 127,422,000Source | 115,771,000Source | 131,749,000Source | 120,775,000Source | 102,577,000Source | 132,187,000Source | 151,024,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 17,100,000Source | 4,300,000Source | 300,000Source | 1,400,000Source | 1,100,000Source | 2,100,000Source | 11,500,000Source | 9,400,000Source | 16,400,000Source | 18,379,242Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -19,000Source | -11,000Source | 58,000Source | 11,000Source | 7,000Source | -337,000Source | -332,000Source | 189,000Source | -40,000Source | -903,611Source |
| General and Administrative ExpenseUSD | — | — | — | 4,500,000Source | 2,292,000Source | 2,621,000Source | 2,126,000Source | 3,146,000Source | 13,816,000Source | 11,039,000Source | 12,039,000Source | 13,070,068Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 7,824,000Source | -13,243,000Source | -5,338,000Source | -11,196,000Source | -5,681,000Source | -12,111,000Source | -46,377,000Source | -43,002,000Source | -47,505,000Source | -47,977,919Source |
| Nonoperating Income (Expense)USD | — | — | 1,087,000Source | 1,216,000Source | 1,146,000Source | 1,317,000Source | 1,119,000Source | 1,481,000Source | 5,031,000Source | 9,875,000Source | 8,258,000Source | 3,366,388Source |
| Operating ExpensesUSD | — | — | -6,737,000Source | 14,459,000Source | 6,484,000Source | 12,513,000Source | 6,782,000Source | 13,592,000Source | 51,408,000Source | 52,877,000Source | 55,756,000Source | -50,985,815Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 11,284,000Source | 27,875,000Source | 20,984,667Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 708,000Source | 2,943,000Source | 691,000Source | 1,776,000Source | 1,010,190Source |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | 2,032,000Source | 4,500,000Source | 2,292,000Source | 2,621,000Source | 2,126,000Source | 3,146,000Source | 13,816,000Source | — | — | — |
| Operating Income (Loss)USD | — | — | 6,737,000Source | -14,459,000Source | -6,484,000Source | -12,513,000Source | -6,782,000Source | -13,592,000Source | -51,408,000Source | -52,877,000Source | -55,756,000Source | -50,985,815Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -46,377,000Source | -43,002,000Source | -47,498,000Source | -47,619,427Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 7,824,000Source | -13,243,000Source | -5,338,000Source | -11,196,000Source | -5,681,000Source | -12,111,000Source | -46,377,000Source | -43,002,000Source | -47,505,000Source | -47,977,919Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.08Source | -0.16Source | -0.06Source | -0.13Source | -0.06Source | -0.14Source | -0.54Source | -0.52Source | -0.6Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | 0.08Source | -0.16Source | -0.06Source | -0.13Source | -0.06Source | -0.14Source | -0.54Source | -0.52Source | -0.6Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 92,696,842,000Source | 85,380,587,000Source | 92,675,753Source | 85,073,769Source | 89,029,458Source | 84,805,974Source | 85,289,447Source | 83,468,049Source | 79,787,596Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 92,899,536,000Source | 85,380,587,000Source | 92,675,753Source | 85,073,769Source | 89,029,458Source | 84,805,974Source | 85,289,447Source | 83,468,049Source | 79,787,596Source | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 7,000Source | 358,492Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -19,000Source | -11,000Source | 58,000Source | 11,000Source | 7,000Source | -337,000Source | -332,000Source | 189,000Source | -40,000Source | -903,611Source |
| General and Administrative ExpenseUSD | — | — | — | 4,500,000Source | 2,292,000Source | 2,621,000Source | 2,126,000Source | 3,146,000Source | 13,816,000Source | 11,039,000Source | 12,039,000Source | 13,070,068Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -44,500,000Source | -39,195,000Source | -41,198,000Source | -40,001,893Source |
| Interest Income (Expense), NetUSD | — | — | 1,072,000Source | 1,075,000Source | 1,061,000Source | 1,210,000Source | 1,079,000Source | 1,394,000Source | 4,678,000Source | 7,320,000Source | 6,519,000Source | 946,988Source |
| Nonoperating Income (Expense)USD | — | — | 1,087,000Source | 1,216,000Source | 1,146,000Source | 1,317,000Source | 1,119,000Source | 1,481,000Source | 5,031,000Source | 9,875,000Source | 8,258,000Source | 3,366,388Source |
| Operating ExpensesUSD | — | — | -6,737,000Source | 14,459,000Source | 6,484,000Source | 12,513,000Source | 6,782,000Source | 13,592,000Source | 51,408,000Source | 52,877,000Source | 55,756,000Source | -50,985,815Source |
| Other IncomeUSD | — | — | 1,087,000Source | 1,216,000Source | 1,146,000Source | 1,317,000Source | 1,119,000Source | 1,481,000Source | 5,031,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | — | 9,959,000Source | 4,192,000Source | 9,892,000Source | 4,656,000Source | 10,446,000Source | 37,592,000Source | 41,838,000Source | 43,717,000Source | 37,915,747Source |
| Taxes, MiscellaneousUSD | — | — | — | — | — | — | — | — | — | — | — | 358,492Source |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
Filing attachments
e8011_ex99-1.htm · 8-K · 2026-10-20
EXHIBIT 99.1 Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical pharmacology characterization across pipeline programs NEW YORK, NY, October 20, 2026 - Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous…
Read attachment ↗e8009_ex99-1.htm · 8-K · 2026-10-15
EXHIBIT 99.1 Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome Anavex now has open INDs in all three core indications: Alzheimer’s disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcamesine oral solution in adult males with Fragile X syndrome NEW YORK, NY, October 15, 2026 - Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company …
Read attachment ↗e7943_ex99-1.htm · DEFA14A · 2026-09-14
EX-99.1 2 e7943_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees ISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS’ Recommendation and Vote “FOR” ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, NY, September 14, 2026 - Anavex Life Sciences Corp. (“Anavex” or “the Company”), a clinical-stage biopharmaceutical company f…
Read attachment ↗e7909_ex99-1.htm · 8-K · 2026-09-02
EX-99.1 2 e7909_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement Anavex Life Sciences is Pleased to Regain Full Compliance with Nasdaq, Continues to Execute on Clinical Development Strategy and Advance all Three Core Indications Forward NEW YORK, NY, September 2, 2026 - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatme…
Read attachment ↗e7897_ex99-1.htm · 8-K · 2026-08-25
EX-99.1 2 e7897_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett Syndrome Formal Meeting Request to FDA, with an IND Submission for Fragile X Syndrome Planned for September NEW YORK, NY, August 25, 20…
Read attachment ↗e7863_ex99-1.htm · DEFA14A · 2026-08-17
EXHIBIT 99.1 Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees Launches VoteAnavex.com to Provide Additional Information on Anavex’s Director Nominees and How to Vote at the Annual Meeting of Stockholders NEW YORK, NY, August 17, 2026 - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) dise…
Read attachment ↗